Daniel Kim to Ipilimumab
This is a "connection" page, showing publications Daniel Kim has written about Ipilimumab.
Connection Strength
0.271
-
Kim DY, Swetter SM, Huhmann L, Dizon MP, Ferguson JM, Osborne TF, Spence AC, Ziad A, Fillmore N, Hartman RI. Real-world effectiveness of immune checkpoint inhibitors and BRAF/MEK inhibitors among veteran patients with cutaneous melanoma. J Am Acad Dermatol. 2024 03; 90(3):620-623.
Score: 0.217
-
Pan CX, Kim DY, Lau CB, Lau WC, Rowley R, Kanwar R, LeBoeuf NR, Nambudiri VE. Comparative analysis of immune-related adverse events among patients with melanoma on immune checkpoint inhibitors: a retrospective cohort study. Br J Dermatol. 2023 10 25; 189(5):637-640.
Score: 0.054